Pfizer wins EU approval for Hympavzi in hemophilia A and B

Pfizer has secured European Commission approval for Hympavzi (marstacimab), a once-weekly anti-tissue factor pathway inhibitor, for routine prophylaxis in adults and adolescents age 12 and older, weighing at least 35 kg, with severe hemophilia A or B without inhibitors. The approval marked another step in the company’s effort to expand its hemophilia portfolio in Europe, following a positive CHMP opinion issued on September 19, 2024, and the product’s U.S. FDA approval on October 11, 2024. (pfizer.com)

The regulatory path was closely watched because Hympavzi offers an alternative to traditional factor replacement regimens, which have typically required intravenous administration. According to the EMA’s product overview, most existing options for severe hemophilia A or B at the time of approval involved repeated factor VIII or IX infusions, while marstacimab works by targeting tissue factor pathway inhibitor to support clot formation through a different mechanism. The EMA concluded that the medicine’s benefits outweighed its risks and authorized it across the EU. (ema.europa.eu)

Pfizer said the EC decision was based on the pivotal Phase 3 BASIS study, which evaluated marstacimab in 116 people with severe hemophilia A or B without inhibitors. In that study, participants received marstacimab during a 12-month active treatment period and were compared with their prior routine prophylaxis regimens during a six-month observational period. Pfizer has also emphasized that Hympavzi is delivered via a pre-filled auto-injector pen, a convenience feature the company says distinguishes it within hemophilia care. (pfizer.com)

The approval also fits into a broader expansion story. In March 2026, CHMP adopted a positive opinion recommending a label expansion for patients with inhibitors, and in May 2026 the European Commission approved that broader indication for patients age 12 and older, weighing at least 35 kg, with hemophilia A with FVIII inhibitors or hemophilia B with FIX inhibitors. Pfizer separately announced a corresponding U.S. approval for two additional patient populations on June 8, 2026. (ema.europa.eu)

Public expert reaction in the source set was limited, but Pfizer’s statements around the inhibitor data framed the product as addressing a meaningful unmet need for patients whose antibodies neutralize factor-based prophylaxis. That messaging aligns with the broader industry view that non-factor therapies are reshaping hemophilia management by reducing treatment burden and broadening prophylaxis options, especially for adolescents and patients seeking subcutaneous administration. This is partly an inference from the regulatory trajectory and Pfizer’s positioning, rather than an independently sourced consensus statement. (pfizer.com)

Why it matters: For veterinary professionals, this isn’t a direct companion-animal therapeutics story, but it is relevant as a window into where biologics development is heading. Human approvals like this often signal platform maturation in monoclonal antibodies, self-administered injectables, and chronic prophylaxis models that can influence expectations among pet parents, investors, and eventually translational research in animal health. It also underscores how regulators are increasingly comfortable with mechanism-based alternatives to replacement therapy when clinical data support reduced bleeding burden and manageable safety profiles. (ema.europa.eu)

For practices and industry watchers, the more immediate takeaway is strategic: Pfizer is steadily building a broader hemophilia franchise across conventional biologics and gene therapy, and Hympavzi gives it a differentiated asset with both U.S. and EU regulatory momentum. Even outside veterinary medicine, that matters because large-company biologics investments often shape manufacturing capacity, pricing expectations, and partnership appetites that spill into adjacent therapeutic areas. This is an inference based on Pfizer’s public hemophilia pipeline activity cited in its release. (pfizer.com)

What to watch: The next milestones are national reimbursement and launch decisions across EU markets, real-world uptake against established prophylaxis options, and any additional regulatory or clinical updates that further expand Hympavzi’s use in inhibitor populations. (pfizer.com)